IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. today announced the publication of a review article covering the company’s Synthetic Triterpenoid programs in the May 2007 issue of the prestigious journal “Nature Reviews Cancer.”
The article, “Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer,” by researchers and Reata scientific collaborators from the Dartmouth Medical School Karen T. Liby, Mark M. Yore and Michael B. Sporn, focuses on two new classes of multifunctional drugs that it reports can prevent and treat cancer in experimental animals. One of Reata’s lead clinical candidates, from one of the classes the article describes, the Synthetic Triterpenoids, is entering advanced clinical trials for deadly, late-stage cancers.
